Paradigm Biopharmaceuticals Ltd (ASX:PAR) has strengthened its team through three new senior executive appointments with commercial head Beverley Huttmann, chief financial officer Justin Cahill and R&D scientist Catherine Stapledon joining the company.
The new executives bring with them skills and experience that further strengthen the capabilities of Paradigm’s management, as the company continues to move toward commercialisation.
Specific expertise added
Paradigm CEO Paul Rennie said: “We are extremely excited to welcome three highly talented and experienced individuals in Beverley, Justin and Catherine to the team.
“Like Paradigm’s recently appointed COO, Dr Jeannie Joughin, Justin also worked for CSL in the USA and was part of CSL’s executive leadership and development program.
“Each brings with them specific expertise and deep knowledge that will greatly assist and enhance the efforts of the current Paradigm staff in their drive to achieving our mission: to develop and commercialise PPS for the treatment of arthralgia driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.”
Implementing commercial strategy
The new commercial head Beverley Huttmann has more than 25 years’ experience with global pharmaceutical companies including CSL and GSK.
Her past responsibilities have encompassed all facets of pharmaceutical commercial management including market and product analysis, strategic planning and budgeting, licensing, pricing and reimbursement, government liaison, in-market promotion, demand forecasting and team leadership.
Huttmann will be responsible for developing and implementing commercial strategy including partnerships, licensing, pricing and reimbursement, product differentiation, patient and physician acceptance and life cycle management.
Financial management
New chief financial officer Justin Cahill is a CPA, holds a masters in accounting and has more than 20 years’ experience in strategic finance roles across a broad spectrum of industries including nine years at CSL and five years in the US as Divisional CFO of CSL Plasma.
As Paradigm’s operations expand and become more global, Cahill will oversee the financial management of and control over the company’s increasingly complex activities.
R&D programs
New R&D translational scientist Catherine Stapledon completed her PhD studies at the Centre for Orthopaedic & Trauma Research, Faculty of Health and Medical Sciences, University of Adelaide where her research involved a multidisciplinary approach to investigate the roles of neurotrophic factors on osteocyte function in osteoarthritis.
Notably, Stapledon’s studies elucidated the mode of action of PPS related to the regulation of Nerve Growth Factor as a mediator of pain in bone osteocytes derived from osteoarthritis patients.
Stapledon will work alongside Paradigm chief science officer Ravi Krishnan where her expertise will be a valuable asset to Paradigm’s R&D programs, involving GLP and GLP-like preclinical proof-of concept studies, and in translational disease models.